


फा.सं. / F. No. 50014/03/2020-CDN  
भारत सरकार / Government of India  
रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers  
औषध विभाग / Department of Pharmaceuticals

शास्त्री भवन, नई दिल्ली  
Shastri Bhawan, New Delhi  
Dated: 18<sup>th</sup> June, 2021

**Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of May, 2021-reg.**

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of May, 2021 for information.

  
(Meera Manggaain)

Under Secretary to the Govt. of India

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal Information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. PSO to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

**Ministry of Chemicals & Fertilizers**  
**Department of Pharmaceuticals**  
**Monthly Summary for the Month of May, 2021**

Important events for the Month of **May, 2021** are as follows:

**(A) IMPORTANT POLICY DECISIONS:**

The Department has taken the following action to deal with the issues arising out of COVID-19 pandemic:

(a) The number of cases of Mucormycosis, a kind of fungal infection, suddenly increased in the country resulting in shortage of the drug required for treating the patients. Apart from measures taken to augment production and import of Liposomal Amphotericin B, a drug required to treat patients of Mucormycosis, a Policy decision was taken in consultation with MoHFW to allocate available Liposomal Amphotericin-B, among States/UTs with an objective to make this drug available in all States/UTs in an equitable manner.

(b) A meeting was held to discuss the issues related to Medical Device industry with respect to COVID-19 with Medical Device Associations under the Chairpersonship of Secretary (Pharma) on 25.05.2021. The representative of medical device industry put the issues being faced by them during the pandemic and also suggested ways to boost manufacturing of medical devices. A Committee with representatives of Associations was constituted on 31.5.2021 for demand assessment in short and medium term of medical devices used in COVID-19, identify the manufacturers of the same and work with them, assess the raw material/ components required for augmenting the desired demand, identify the raw material/ component manufacturers and work with them. The Committee will submit its report on 14.06.2021.

**(B) MAJOR ACHIEVEMENTS:**

**I. National Pharmaceutical Pricing Authority (NPPA):**

(i) The NPPA has fixed ceiling prices of 01 medicine during May, 2021 bringing the cumulative figure to 884 till May, 2021.

(ii) Retail prices of 2 new medicines have been fixed during May, 2021 bringing cumulative figure to 1533 till May, 2021.

(iii) Total overcharged amount received during May, 2021 is Rs. 28.24 Lakhs.

**II. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):**

59 new Jan Aushadhi Kendras under Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) opened during the month across the country.

### **III. National Institutes of Pharmaceutical Education and Research (NIPERs)**

- a. Out of 90 Research Papers published during the current financial year, 44 papers has been published in May, 2021.
- b. Out of 4 Patents filed during the current financial year, 2 patents has been filed during the May,2021
- c. Department has accepted the report on Financial Resilience and Medical device Testing prepared by NIPER Guwahati and NIPER Ahmedabad respectively.

### **IV. COVID-related activities:**

a) The Department of Pharmaceuticals and the Department of Health and Family Welfare are working very closely on the issue of augmenting availability of drugs required for management of COVID-19. The issues pertain to production of drugs listed in clinical management protocol, their imports, imports of raw material, issues with respect to restriction/prohibition of exports, allocation of drugs under shortage to States/UTs in an equitable manner etc. Further, for more systematic coordination and for bringing in efficiency in terms of decision making, a Drugs Coordination Committee (DCC) under the chair of Secretary, Pharmaceuticals was formed vide OM No. 31025/25/2021-Policy, dated 20<sup>th</sup> May, 2021. Two meetings of the DCC were held during the month of May, 2021 wherein discussions inter-alia on (i) review of Remdesivir availability and decision to restrict allocation to only procurement by HLL in view of overall augmented availability; (ii) review of supply of Amphotericin-B and recommending restriction on exports for Amphotericin-B injection; (iii) direction to DCGI w.r.t. monitoring production, supply, stock of data of essential drugs for treatment of Covid-19 and Mucormycosis took place.

Also, Meeting with manufacturers to review the current production capacity of API required for COVID drugs and Mucormycosis drugs was held on 25th May, 2021 wherein it was conveyed that there is a need to make an assessment plan for the next 6 months to ramp-up production and share with DoP any problem in getting KSMs or any other consumables/excipients etc., to facilitate building in resilience to respond to sudden surge in demand. Also, manufacturing of Enoxaparin/Heparin and IvIG for treatment of Covid-19 was also reviewed with the major firms along with the participation of DCGI.

#### **b) NPPA:**

- i. 1121 complaints received during May, 2021 were addressed and resolved, solutions provided or forwarded to concerned authorities for redressal.
- ii Supply of Remdesivir/Tocilizumab and Amphotericin to States/UTs monitored across the country
- iii Undertook price monitoring of Pulse Oximeters and Oxygen Concentrators under Para 20 of the DPCO, 2013 to ensure increase in MRP for last 12 months was not more than 10%.

**V. Budget Expenditure:**

In the Financial Year 2021-22, the total budget allocated to Department of Pharmaceuticals Rs. 432.70 Cr and the details of expenditure incurred are as below:

Total Budget allocated	Expenditure incurred (as on 28.05.2021)	(Rs. in Crore)
		Expenditure incurred in the month of May, 2021
Rs. 432.70	Rs. 25.80	22.55

(C) The details of grievances during the May, 2021 are as under:

No. of grievances at the start of the month	No. of grievances received during the month	No. of grievances disposed	No. of grievances pending at end of the month
128	371	312	187

(D) FDI proposals:-

- a. Pending at beginning of the month :- (12)
- b. Received during the month :- (0)
- c. Disposed of during the month :- (1)
- d. Pending at end of the month :- (11)

\*\*\*\*\*